Abstract
Background HPV-16 infections constitute the highest risk for developing uterine cervix cancer. However, the role of other high-risk types is still controversial.
Objective To analyze HR-HPV prevalence and its possible associations between HPV and risk factors related to cervical lesions among Mexican women.
Methods Cross sectional study using 362 cervical samples collected between 2016 and 2017. Fourteen HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) were detected by highly sensitive PCR amplification followed by reverse hybridization. Bivariate and multivariate analyses were performed to investigate the association between HPV types and risk factors among lesions.
Results Most samples were HR-HPV positive (83.43%). HPV-16 was the most prevalent infection among negative for intraepithelial lesions or malignancy (78.6%), high-grade squamous intraepithelial lesions (50%), and cervical cancer (58.2%). HPV-66 showed an unexpected high prevalence in atypical squamous cells of undetermined significance (50%), low-grade squamous intraepithelial (45.7%), and only found in 3.6% of cervical cancers. HPV-16 was significantly prevalent among women between 30-39 years, whereas types 66 and 52 were significantly associated when previously sexually transmitted disease had occurred (p< 0.05).
Conclusions HPV-66 either in single or co-infection with other HR-HPV types (excluding 16 and 18) might be indicative of non-progressive cancer lesions. HPV-66 prevalence was unusually high in low-grade cervical lesions, predominantly in co-infection with HPV-51, and very low among cervical cancer. This should be addressed to interpret results obtained by methods that group type 66 with other HR-types.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This transversal study was realized at Instituto Mexicano del Seguro Social (IMSS), Mexico City, with approval number 2014-3505-6 by the Ethics Committee. Informed consent signed by each participant,
Funding Statement
This project was supported by CONACyT Sectoral Funds (FOSISS) SALUD-2014-C01-234198. PROT/FIS/IMSS 1377. To the team of Cellular Pathology and Molecular Cancer Laboratory, UIMEO HO. CMN SXXI, IMSS. This work was partially supported by a grant to AG-C from PAPIIT-UNAM (IN213016).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
- JG
- Juárez González
- PC
- Paredes Cervantes
- GR
- Gordillo Rodríguez
- GG
- González Guzmán
- MV
- Moncayo Valencia
- MM
- Méndez Martínez
- GC
- García Carrancá
- ME
- Martínez Ezquerro
- RR
- Rivas Ruíz
- SS
- Sánchez Suárez
- AS
- Alvarez Sandoval
- PA
- Padilla Arrieta
- MS
- Martínez Salazar
- VV
- Vázquez Vega
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.